Psyence Group

Psyence Group Inc is pioneering the use of natural psilocybin for the long-term treatment of trauma and its mental health consequences.In January 2023, Psyence Group Inc entered into a definitive business combination agreement with Psyence Biomed Corp.In april 2023, Psyence group Inc issued 9,043,038 shares at a price of CAD$0.12 per shareIn December 2022, Psyence Group Inc closed the second tranche of its previously announced private placement of CAD$3 million. The Company has issued 7,751,859 common shares at CAD$0.12 per common share for gross proceeds of CAD$930,223 in addition to the previously announced closing of the first tranche for gross proceeds of CAD$1.22 million led by Brandon Kerzner.In November 2022, the company secured subscription agreements of CAD$1.22 million in gross earnings.In January 2021, the Company issued outstanding share capital consists of 85,528,931 shares outstanding and 101,871,539 shares outstanding on a fully diluted basis